Security key
03879J100
Arbutus Biopharma Corp - Common Shares, without par value (ABUS)
CUSIP: 03879J100
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Shares, without par value
- Total 13F shares
- 1,289,178
- Total 13F value
- $6,187,420
- Share change
- +171,287
- SEC-reported price per share
- $4.80
- Number of holders
- 25
- Value change
- +$822,293
- Number of buys
- 5
- Number of sells
- 9
- Shares outstanding
- 197,420,670
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
25
Top holders
10
ABUS full security history
Ownership snapshot
Full 13F holder table
Arbutus Biopharma Corp SEC filings
Arbutus Biopharma Corp company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03879J100
Recent filing periods:
Ownership snapshot
Top reported holders of ABUS - Arbutus Biopharma Corp - Common Shares, without par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Roivant Sciences Ltd.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
15/15
Latest evidence
24 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
13D/G row: Roivant Sciences Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Roivant Sciences Ltd. leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Roivant Sciences Ltd.'s linked filing trail.
Comparable ownership
Top 5
Roivant Sciences Ltd.
20%
MORGAN STANLEY
14%
Two Seas Capital LP
9.4%
Whitefort Capital Management, LP
8%
BlackRock, Inc.
6.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. |
13D/G
3/4/5
10%+ Owner
|
20%
|
$127,808,150
38,847,462 shares
|
$0 | 21 Feb 2025 |
| MORGAN STANLEY |
13D/G
13F
Company
|
14%
|
$122,814,997
25,910,337 shares
|
+$20,788,104 | 31 Dec 2025 |
| Two Seas Capital LP |
13F
13D/G
Company
|
9.4%
from 13D/G
|
$83,508,944
18,557,543 shares
|
— | 31 Mar 2026 |
| Whitefort Capital Management, LP |
13D/G
13F
Whitefort Capital Master Fund, LP · Company
|
8%
|
$71,074,174
15,794,261 shares
|
$0 | 24 Apr 2026 |
| BlackRock, Inc. |
13F
Company
|
6.6%
|
$58,351,259
12,966,946 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.4%
|
$30,100,100
6,688,911 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
25
Shares
1,289,178
Rows available
25
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
166
Q2 2026 holders
25
Holder diff
-141
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend